SUPPORT Novartis TO FIGHT AGAISNT MALARIA

Malaria No More and Novartis launch Power of One, a global digital fundraising campaign to help eliminate malaria deaths.

September 23, 2013

• Power of One enables the public to fund malaria tests and treatments for children in Africa through the latest online and mobile technology
• Novartis is the exclusive campaign treatment sponsor and will donate up to three million full courses of Coartem® Dispersible, its pediatric antimalarial, doubling the impact of public donations
• Novartis, a long-standing leader in malaria control and elimination, has delivered 200 million pediatric antimalarial treatments without profit to malaria-endemic countries since 2009

Basel, Switzerland, September 23, 2013 - Novartis and Malaria No More announced today the debut of the Power of One campaign, encouraging people around the world to help end child deaths from malaria. Novartis will support the campaign financially and donate up to three million Coartem® Dispersible treatments to match antimalarials funded by the public. The company’s commitment to Power of One aligns with its long history in the fight against malaria; the Novartis Malaria Initiative is one of the largest access-to-medicine programs in the healthcare industry.
Malaria is a preventable and treatable disease, but it still kills a child every minute. It is estimated that over 300 million additional treatments will be needed to treat malaria patients across Africa between now and the end of 2015. The Power of One campaign aims to address this treatment gap through direct donations and existing government commitments. Every dollar donated to the campaign will buy and deliver a treatment to a child diagnosed with malaria.
“I am proud of the significant and longstanding commitment Novartis has to the fight against malaria. For all our progress though, there’s still more work to do” said Joseph Jimenez, CEO of Novartis. “We need more help to close the treatment gap and Power of One offers everyone a chance to engage and make a difference for children suffering from malaria.”
Harnessing social, mobile, and e-commerce technologies, Power of One enables the public to purchase a treatment and track the journey of a treatment. Donors will be able to see the effect of their donation on the ground, share information with their networks and recruit other donors.
It’s unacceptable that a child dies every minute for lack of a dollar’s worth of treatment,” said Martin Edlund, CEO, Malaria No More. “We’re urging the
world to join the Power of One campaign and to donate and engage their friends in this fight.”
Novartis is the exclusive treatment sponsor of the Power of One campaign, joining some of the world’s most innovative companies. Additional sponsors include Alere Inc., which will provide malaria rapid diagnostic tests, 21st Century Fox, AHAlife.com, Causes.com, Time Warner, Twitter, Venmo and others. Zambia will be the first country to receive deliveries of treatments and tests as a result of the Power of One campaign.

Novartis reaches 200 million deliveries of Coartem® Dispersible

Since 2009, Novartis has delivered 200 million treatments of its pediatric antimalarial Coartem® Dispersible without profit to more than 50 malaria-endemic countries. Never before have so many pediatric treatments been distributed in such a short time frame for children suffering from malaria. The 200 millionth treatment was delivered to Zambia, which also received the first consignment of Novartis treatments for the Power of One campaign, raised during World Malaria Day on April 25, 2013.
“MMV applauds Novartis on this laudable achievement,” said David Reddy, CEO of Medicines for Malaria Venture. “Novartis has done a tremendous job of bringing an innovative drug to the vulnerable young victims of malaria in Zambia and over 50 other countries, giving it global reach. We at MMV are proud to have partnered with Novartis on the development of this important formulation.”
The Novartis Malaria Initiative is one of the largest access-to-medicine programs in the healthcare industry. Moving forward, Novartis is committed to malaria elimination by driving the development of the next generation antimalarials, with two new classes of anti-malaria drugs currently in development. The most advanced compound is in Phase II clinical trials.
For more information: www.malaria.novartis.com.

About Novartis

Novartis provides innovative healthcare solutions that address the evolving needs of patients and societies. Headquartered in Basel, Switzerland, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, eye care, cost-saving generic pharmaceuticals, preventive vaccines and diagnostic tools, over-the-counter and animal health products. Novartis is the only global company with leading positions in these areas. In 2012, the Group achieved net sales of USD 56.7 billion, while R&D throughout the Group amounted to approximately USD 9.3 billion (USD 9.1 billion excluding impairment and amortization charges). Novartis Group companies employ approximately 128,000 full-time-equivalent associates and operate in more than 140 countries around the world. For more information, please visit www.novartis.com.

MALARIA KILLS EVEN FASTER THAN AIDS

What is malaria?
Malaria is a serious disease that causes a high fever and chills. You can get it from a bite by an infected mosquito. Malaria is rare in the United States. It is most often found in Africa, Southern Asia, Central America, and South America.
What causes malaria?
Malaria is caused by a bite from a mosquito infected with parasites. In very rare cases, people can get malaria if they come into contact with infected blood. A developing fetus may get the disease from its mother. You cannot get malaria just by being near a person who has the disease.
What are the symptoms?
Most malaria infections cause symptoms like the flu, such as a high fever, chills, and muscle pain. Symptoms tend to come and go in cycles. One type of malaria may cause more serious problems, such as damage to the heart, lungs, kidneys, or brain. It can even be deadly.
How is malaria diagnosed?
Your doctor will order a blood test to check for the malaria parasite in your blood.
How is it treated?
Medicines usually can treat the illness. But some malaria parasites may survive because they are in your liver or they are resistant to the medicine.
Call a doctor right away if you have been in an area where malaria is present, were exposed to mosquitoes, and get symptoms that are like the flu. These include a high fever, chills, and muscle pain.
How is malaria prevented?
You may be able to prevent malaria by taking medicine before, during, and after travel to an area where malaria is present. But using medicine to prevent malaria doesn't always work. This is partly due to the parasites being resistant to some medicines in some parts of the world.

PROVIDING TREATMENT FOR CHILDREN'S MEDICAL EMERGENCIES

 

Living in poverty is difficult enough. But families can be devastated when severe conditions like cancer, heart disease or traumatic injury occur and no money is available for treatment.
Compassion steps in to help with situations that include surgery, vision and hearing issues, prosthetic limbs, wheelchairs, trauma counseling, special dental needs and funeral expenses.
Our assistance covers medical needs but also helps individuals continue functioning. Children can also stay with their families as they recover.

 
Ammy was born with retinoblastoma, a malignant, metastatic cancer. Without surgery to remove her eyes, the cancer would spread to her brain and she would not make it to her first birthday.
When Ammy was 8 weeks old, surgeons removed both of her eyes. Her recovery was slow and painful, and her family fell deep into debt. Then her mother Lourdes discovered Compassion and saw how the staff looked into her daughter's face with no disgust or fear.
Compassion workers arranged for Ammy to be fitted with prosthetic eyes. The medical program covered Ammy's bills, and a month later Lourdes held Ammy in her arms, staring in wonder at her daughter's blinking brown eyes.